Characteristics of patients surviving beyond 3 years compared with those who died within 1 year after transplant
| Variables∗ . | Died within 1 y (n = 58) . | Survived beyond 3 y (n = 21) . | P value . |
|---|---|---|---|
| Age at diagnosis, y | 62.0 (20.2-74.3) | 62.9 (36.1-71.0) | .93 |
| Age at alloHCT, y | 63.7 (20.5-75.2) | 64.3 (36.5-72.9) | .79 |
| Gender, male (n = 79), n (%) | 32 (55.2) | 13 (61.9) | .78 |
| Therapy-related MN (n = 79), n (%) | 30 (51.7) | 7 (33.3) | .23 |
| Variables at diagnosis | |||
| Hemoglobin, g/dL | 8.50 (6.90-13.2) | 9.50 (5.40-14.7) | .33 |
| WBC, ×109/L | 3.15 (0.600-192) | 1.85 (0.600-6.30) | .034 |
| Platelets, ×109/L | 80.5 (6.00-445) | 78.0 (11.0-596) | .88 |
| Peripheral blood blasts, % | 1.50 (0-96.0) | 0 (0-30.0) | .16 |
| Peripheral blood blasts >5% (n = 72), n (%) | 21 (36.2) | 3 (14.3) | .15 |
| BM blasts, % | 13.0 (0-92.0) | 20.0 (0-89.0) | .66 |
| BM blasts ≥10% (n = 78), n (%) | 33 (57.9) | 14 (66.7) | .47 |
| Abnormal karyotype (n = 76), n (%) | 53 (91.4) | 18 (85.7) | .65 |
| Chromosome 5 abnormality type (n = 73), (%) | .64 | ||
| Deletion 5q | 28 (48.3) | 11 (52.4) | |
| Deletion 5q and monosomy 5 | 3 (5.2) | 1 (4.8) | |
| Monosomy 5 | 9 (15.5) | 3 (14.3) | |
| Other | 6 (10.3) | 0 (0) | |
| No abnormality | 8 (13.8) | 4 (19.0) | |
| Chromosome 7 abnormality type (n = 73), n (%) | .94 | ||
| Deletion 7q or monosomy 7 | 22 (37.9) | 7 (33.3) | |
| Other | 9 (15.5) | 3 (14.3) | |
| No abnormality | 23 (39.7) | 9 (42.9) | |
| Chromosome 17 abnormality type (n = 77), n (%) | .17 | ||
| Abnormal 17p or monosomy 17 | 22 (37.9) | 4 (19.0) | |
| Other | 6 (10.3) | 1 (4.8) | |
| No abnormality | 29 (50.0) | 15 (71.4) | |
| CK at diagnosis (n = 78), n (%) | 51 (87.9) | 17 (81.0) | .54 |
| Maximum TP53mut VAF | 48.3 (6.00-96.0) | 26.0 (5.00-70.8) | .002 |
| TP53 VAF ≥10% (n = 74), n (%) | 52 (89.7) | 12 (57.1) | .015 |
| TP53 VAF ≥50% (n = 72), n (%) | 26 (44.8) | 3 (14.3) | .058 |
| Non-DBD TP53mut (n = 76), n (%) | 7 (12.1) | 3 (14.3) | 1 |
| DNMT3A comutation present (n = 79), n (%) | 4 (6.9) | 1 (4.8) | 1 |
| Phenotype (n = 79), n (%) | .003 | ||
| MDS, other | 4 (6.9%) | 3 (14.3%) | |
| AML, other | 2 (3.4) | 7 (33.3) | |
| MDS with TP53mut | 21 (36.2) | 5 (23.8) | |
| MDS/AML with TP53mut | 9 (15.5) | 1 (4.8) | |
| AML with TP53mut | 22 (37.9) | 5 (23.8) | |
| DMT pre-alloHCT (n = 79), n (%) | |||
| Any | 53 (91.4) | 19 (90.5) | 1 |
| Intensive therapy (vs nonintense therapy) | 23 (43.4) | 8 (42.1) | 1 |
| Venetoclax | 20 (34.5) | 4 (19.0) | .28 |
| Variables available at HCT, n (%) | |||
| Deletion 17p (n = 62) | 7 (12.1) | 1 (4.8) | .38 |
| Abnormal chromosome 17 (n = 64) | 14 (24.1) | 2 (9.5) | .12 |
| CK (n = 64) | 28 (48.3) | 7 (33.3) | .063 |
| MRD positive pre-alloHCT (n = 22) | 10 (17.2) | 1 (4.8) | .31 |
| Residual disease present pre-alloHCT (n = 78) | 41 (70.7) | 11 (52.4) | .18 |
| BM blasts ≥5% (n = 77) | 9 (15.5) | 0 (0) | .12 |
| Melphalan (n = 79) | 26 (44.8) | 14 (66.7) | .14 |
| Busulfan (n = 79) | 25 (43.1) | 6 (28.6) | .36 |
| Cyclophosphamide (in conditioning, n = 79) | 10 (17.2) | 4 (19.0) | 1 |
| Total body irradiation (n = 79) | 8 (13.8) | 1 (4.8) | .47 |
| Myeloablative conditioning (n = 78) | 14 (24.1) | 5 (23.8) | 1 |
| Variables∗ . | Died within 1 y (n = 58) . | Survived beyond 3 y (n = 21) . | P value . |
|---|---|---|---|
| Age at diagnosis, y | 62.0 (20.2-74.3) | 62.9 (36.1-71.0) | .93 |
| Age at alloHCT, y | 63.7 (20.5-75.2) | 64.3 (36.5-72.9) | .79 |
| Gender, male (n = 79), n (%) | 32 (55.2) | 13 (61.9) | .78 |
| Therapy-related MN (n = 79), n (%) | 30 (51.7) | 7 (33.3) | .23 |
| Variables at diagnosis | |||
| Hemoglobin, g/dL | 8.50 (6.90-13.2) | 9.50 (5.40-14.7) | .33 |
| WBC, ×109/L | 3.15 (0.600-192) | 1.85 (0.600-6.30) | .034 |
| Platelets, ×109/L | 80.5 (6.00-445) | 78.0 (11.0-596) | .88 |
| Peripheral blood blasts, % | 1.50 (0-96.0) | 0 (0-30.0) | .16 |
| Peripheral blood blasts >5% (n = 72), n (%) | 21 (36.2) | 3 (14.3) | .15 |
| BM blasts, % | 13.0 (0-92.0) | 20.0 (0-89.0) | .66 |
| BM blasts ≥10% (n = 78), n (%) | 33 (57.9) | 14 (66.7) | .47 |
| Abnormal karyotype (n = 76), n (%) | 53 (91.4) | 18 (85.7) | .65 |
| Chromosome 5 abnormality type (n = 73), (%) | .64 | ||
| Deletion 5q | 28 (48.3) | 11 (52.4) | |
| Deletion 5q and monosomy 5 | 3 (5.2) | 1 (4.8) | |
| Monosomy 5 | 9 (15.5) | 3 (14.3) | |
| Other | 6 (10.3) | 0 (0) | |
| No abnormality | 8 (13.8) | 4 (19.0) | |
| Chromosome 7 abnormality type (n = 73), n (%) | .94 | ||
| Deletion 7q or monosomy 7 | 22 (37.9) | 7 (33.3) | |
| Other | 9 (15.5) | 3 (14.3) | |
| No abnormality | 23 (39.7) | 9 (42.9) | |
| Chromosome 17 abnormality type (n = 77), n (%) | .17 | ||
| Abnormal 17p or monosomy 17 | 22 (37.9) | 4 (19.0) | |
| Other | 6 (10.3) | 1 (4.8) | |
| No abnormality | 29 (50.0) | 15 (71.4) | |
| CK at diagnosis (n = 78), n (%) | 51 (87.9) | 17 (81.0) | .54 |
| Maximum TP53mut VAF | 48.3 (6.00-96.0) | 26.0 (5.00-70.8) | .002 |
| TP53 VAF ≥10% (n = 74), n (%) | 52 (89.7) | 12 (57.1) | .015 |
| TP53 VAF ≥50% (n = 72), n (%) | 26 (44.8) | 3 (14.3) | .058 |
| Non-DBD TP53mut (n = 76), n (%) | 7 (12.1) | 3 (14.3) | 1 |
| DNMT3A comutation present (n = 79), n (%) | 4 (6.9) | 1 (4.8) | 1 |
| Phenotype (n = 79), n (%) | .003 | ||
| MDS, other | 4 (6.9%) | 3 (14.3%) | |
| AML, other | 2 (3.4) | 7 (33.3) | |
| MDS with TP53mut | 21 (36.2) | 5 (23.8) | |
| MDS/AML with TP53mut | 9 (15.5) | 1 (4.8) | |
| AML with TP53mut | 22 (37.9) | 5 (23.8) | |
| DMT pre-alloHCT (n = 79), n (%) | |||
| Any | 53 (91.4) | 19 (90.5) | 1 |
| Intensive therapy (vs nonintense therapy) | 23 (43.4) | 8 (42.1) | 1 |
| Venetoclax | 20 (34.5) | 4 (19.0) | .28 |
| Variables available at HCT, n (%) | |||
| Deletion 17p (n = 62) | 7 (12.1) | 1 (4.8) | .38 |
| Abnormal chromosome 17 (n = 64) | 14 (24.1) | 2 (9.5) | .12 |
| CK (n = 64) | 28 (48.3) | 7 (33.3) | .063 |
| MRD positive pre-alloHCT (n = 22) | 10 (17.2) | 1 (4.8) | .31 |
| Residual disease present pre-alloHCT (n = 78) | 41 (70.7) | 11 (52.4) | .18 |
| BM blasts ≥5% (n = 77) | 9 (15.5) | 0 (0) | .12 |
| Melphalan (n = 79) | 26 (44.8) | 14 (66.7) | .14 |
| Busulfan (n = 79) | 25 (43.1) | 6 (28.6) | .36 |
| Cyclophosphamide (in conditioning, n = 79) | 10 (17.2) | 4 (19.0) | 1 |
| Total body irradiation (n = 79) | 8 (13.8) | 1 (4.8) | .47 |
| Myeloablative conditioning (n = 78) | 14 (24.1) | 5 (23.8) | 1 |
Boldface values indicate statistically significant at P < 0.05.
Median (min-max) unless specified otherwise.